Last mentioned: 2d ago
Insider Selling
President and another insider report share sales in regulatory filings.
Analyst Downgrade
Wall Street Zen cuts ALHC rating to Hold.
Offering Priced
Secondary offering is priced at $19.46 per share.
Secondary Offering Announced
Company announces intent to sell 13.2 million shares to raise capital.
Expected Q4 Earnings Call
Management is anticipated to provide final 2025 figures and formal guidance for the 2026 fiscal year.
Q4 Earnings Report
Alignment Healthcare reports a declining net loss for the fourth quarter of 2025.
Earnings Preview Release
FinancialContent and other market trackers highlight ALHC as a key stock to watch ahead of Q4 reporting.
Baird Model Update
Analysts at Baird set a bullish $59 price target for ALHC, signaling high confidence in the tech-enabled MA model.
Alignment Healthcare (NASDAQ: ALHC) has reported significant insider selling, including a 29,113-share disposal by its President, shortly after a major secondary offering. These transactions occur as the company navigates a shift in analyst sentiment and a challenging regulatory environment for Medicare Advantage providers.
Wall Street Zen has lowered its rating on Alignment Healthcare (ALHC) to "Hold," reflecting broader caution within the Medicare Advantage sector. The downgrade comes as specialized insurers face tightening margins and regulatory shifts in the federal reimbursement landscape.
Alignment Healthcare (ALHC) is set to report its fourth-quarter results, with investors focusing on membership growth and the medical loss ratio (MLR) within its tech-enabled Medicare Advantage platform. As the MA market faces regulatory headwinds, ALHC's ability to maintain clinical outcomes through its proprietary AVA software remains a critical differentiator.